JP2013511288A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511288A5
JP2013511288A5 JP2012540240A JP2012540240A JP2013511288A5 JP 2013511288 A5 JP2013511288 A5 JP 2013511288A5 JP 2012540240 A JP2012540240 A JP 2012540240A JP 2012540240 A JP2012540240 A JP 2012540240A JP 2013511288 A5 JP2013511288 A5 JP 2013511288A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012540240A
Other languages
English (en)
Japanese (ja)
Other versions
JP5816188B2 (ja
JP2013511288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/001882 external-priority patent/WO2011063523A1/en
Publication of JP2013511288A publication Critical patent/JP2013511288A/ja
Publication of JP2013511288A5 publication Critical patent/JP2013511288A5/ja
Application granted granted Critical
Publication of JP5816188B2 publication Critical patent/JP5816188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012540240A 2009-11-24 2010-11-24 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用 Active JP5816188B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26386509P 2009-11-24 2009-11-24
US61/263,865 2009-11-24
PCT/CA2010/001882 WO2011063523A1 (en) 2009-11-24 2010-11-24 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Publications (3)

Publication Number Publication Date
JP2013511288A JP2013511288A (ja) 2013-04-04
JP2013511288A5 true JP2013511288A5 (enExample) 2013-12-12
JP5816188B2 JP5816188B2 (ja) 2015-11-18

Family

ID=44065791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540240A Active JP5816188B2 (ja) 2009-11-24 2010-11-24 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用

Country Status (13)

Country Link
US (3) US8802826B2 (enExample)
EP (1) EP2504363B1 (enExample)
JP (1) JP5816188B2 (enExample)
CN (1) CN102666585B (enExample)
AU (1) AU2010324506B2 (enExample)
CA (2) CA2776513C (enExample)
DK (1) DK2504363T3 (enExample)
EA (1) EA034462B1 (enExample)
ES (1) ES2734886T3 (enExample)
HR (1) HRP20191129T1 (enExample)
PT (1) PT2504363T (enExample)
RU (1) RU2627163C2 (enExample)
WO (1) WO2011063523A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
EA201491568A1 (ru) * 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака
CA2900533A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Anti-clusterin monotherapy for cancer treatment
CN104267187A (zh) * 2014-10-15 2015-01-07 吉林大学 检测尿液Clusterin含量试纸条的制备及应用
CN105988004B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1胶体金定量检测试纸卡
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
CN111093693B (zh) * 2017-06-15 2024-08-09 纪念斯隆-凯特林癌症中心 抗l1-cam抗体及其用途
CN107353341B (zh) * 2017-08-17 2020-03-27 联合益康(北京)生物科技有限公司 一种抗clu抗体及应用、制备方法和试剂盒
WO2020018364A1 (en) * 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CA3173818A1 (en) * 2021-04-27 2022-10-27 Alethia Biotherapeutics Inc. Tumor infiltrating lymphocytes therapy
IL307954A (en) * 2021-04-27 2023-12-01 Alethia Biotherapeutics Inc A method that allows immune system cells to penetrate tumors
US20250195647A1 (en) * 2023-12-13 2025-06-19 Corbus Pharmaceuticals, Inc. ANTI-alpha-V-beta-8 INTEGRIN ANTIBODIES AND USES THEREOF
WO2025147775A1 (en) * 2024-01-10 2025-07-17 Alethia Biotherapeutics Inc. Combination therapy for neoadjuvant treatment of cancer

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3933850A1 (de) 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
WO1999012558A1 (en) 1997-09-10 1999-03-18 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2001245280A1 (en) 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
US7279294B2 (en) 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2004521627A (ja) 2001-02-09 2004-07-22 インサイト・ゲノミックス・インコーポレイテッド 細胞増殖、細胞分化および細胞死に関連するタンパク質
CA2443644A1 (en) 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
RU2335507C2 (ru) 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
JP2005538706A (ja) * 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
US20030134301A1 (en) 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003054152A2 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR101166214B1 (ko) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
EP1487857A4 (en) 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003281287A1 (en) 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
CA2882443C (en) 2002-08-21 2016-12-13 The University Of British Columbia Rnai probes targeting cancer-related proteins
DE60333839D1 (de) 2002-08-21 2010-09-30 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20050048490A1 (en) 2002-09-26 2005-03-03 Incyte Corp. Proteins associated with cell growth, differentiation, and death
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
EP1603514A4 (en) 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR THYROID CANCER AND APPLICATION METHOD
WO2005049806A2 (en) 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2006523199A (ja) 2003-03-28 2006-10-12 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 末梢神経疾患の治療及び/又は予防のためのクラステリンの使用
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20040220131A1 (en) 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
JP2007523839A (ja) 2003-04-18 2007-08-23 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 血管新生性障害の治療法
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
JP2007507204A (ja) 2003-07-29 2007-03-29 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005026209A2 (en) 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
EP1708961B1 (en) 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
GB0329254D0 (en) 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
WO2005071059A2 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
KR20070049637A (ko) 2004-07-09 2007-05-11 트리패스 이미징, 인코포레이티드 난소 질환 검출 방법 및 조성물
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
US20080014198A1 (en) 2004-11-23 2008-01-17 The University Of British Columbia Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
JP2008528033A (ja) 2005-01-27 2008-07-31 ファイブ プライム セラピューティクス, インコーポレイテッド ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
WO2006089586A1 (en) 2005-02-23 2006-08-31 Medizinische Universität Graz Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins
US7678371B2 (en) 2005-03-04 2010-03-16 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
US20100035970A1 (en) 2005-04-15 2010-02-11 Oncomethylome Sciences, S.A. Methylation Markers for Diagnosis and Treatment of Cancers
WO2007022248A2 (en) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20090181380A1 (en) 2005-12-19 2009-07-16 Abdelmajid Belouchi Genemap of the human genes associated with crohn's disease
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
KR100679173B1 (ko) 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트
RS51723B2 (sr) * 2006-03-23 2018-03-30 Bioarctic Neuroscience Ab Poboljšana antitela selektivna za protofibrile i njihova primena
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2087152B1 (en) 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin
US8568993B2 (en) 2007-07-02 2013-10-29 Purdue Research Foundation Detection of glycopeptides and glycoproteins for medical diagnostics
WO2009034562A2 (en) 2007-09-11 2009-03-19 Dublin City University A method of assessing lung squamous cell carcinoma status in an individual
WO2009061382A2 (en) 2007-11-02 2009-05-14 Marban Eduardo T Cardiac stem cell and myocyte secreted paracrine factors and uses thereof
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
EP2071336A1 (en) 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2240196A2 (en) 2008-01-22 2010-10-20 Compugen Ltd. Clusterin derived peptide
WO2009116860A1 (en) 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
KR101110758B1 (ko) 2008-06-02 2012-02-15 경북대학교 산학협력단 뇌졸중 표적용 펩티드 및 이의 용도
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010030980A2 (en) 2008-09-12 2010-03-18 University Of South Florida Akt and clusterin as biomarkers of chemotherapeutic responsiveness
WO2010118521A1 (en) 2009-04-17 2010-10-21 National Research Council Of Canada Peptide ligands for clusterin and uses thereof
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
EA201491568A1 (ru) 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака

Similar Documents

Publication Publication Date Title
JP2013511288A5 (enExample)
RU2012126098A (ru) Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP2013506428A5 (enExample)
JP2018504105A5 (enExample)
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
JP2012100677A5 (enExample)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
JP2008538289A5 (enExample)
Chen et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
JP2010535713A5 (enExample)
JP2019510733A5 (enExample)
JP2015535828A5 (enExample)
JP2013517487A5 (enExample)
HRP20171274T1 (hr) U potpunosti ljudska antitijela specifična za cadm1
JP2019535670A5 (enExample)
JP2011207882A5 (enExample)
JP2011505146A5 (enExample)
JP2020502271A5 (enExample)
JP2016537383A5 (enExample)
JP2018008949A5 (enExample)
JP2014522850A5 (enExample)
JP2017149720A5 (enExample)
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
RU2013128444A (ru) Новые модуляторы и способы их применения
JP2014526898A5 (enExample)